Your browser doesn't support javascript.
loading
Arthralgia and myalgia associated with aromatase inhibitors: frequency and characterization in real-life patients.
Camejo, Natalia; Castillo, Cecilia; Santana, Diego; Argenzio, Lucia; Amarillo, Dahiana; Herrera, Guadalupe; Guerrina, Maria; Krygier, Gabriel.
Afiliación
  • Camejo N; Oncology Service, Hospital de Clínicas Dr. Manuel Quintela, Montevideo 11600, Uruguay.
  • Castillo C; Oncology Service, Departmental Hospital of Soriano "Zoilo A. Chelle" - U.E 30. Soriano, 75000, Uruguay.
  • Santana D; Oncology Service, Hospital de Clínicas Dr. Manuel Quintela, Montevideo 11600, Uruguay.
  • Argenzio L; Oncology Service, Hospital de Clínicas Dr. Manuel Quintela, Montevideo 11600, Uruguay.
  • Amarillo D; Oncology Service, Hospital de Clínicas Dr. Manuel Quintela, Montevideo 11600, Uruguay.
  • Herrera G; Oncology Service, Hospital de Clínicas Dr. Manuel Quintela, Montevideo 11600, Uruguay.
  • Guerrina M; Department of Quantitative Methods, School of Medicine, Montevideo 11800, Uruguay.
  • Krygier G; Oncology Service, Hospital de Clínicas Dr. Manuel Quintela, Montevideo 11600, Uruguay.
Ecancermedicalscience ; 18: 1697, 2024.
Article en En | MEDLINE | ID: mdl-38774562
ABSTRACT

Introduction:

Adjuvant treatment with aromatase inhibitors (AI) in oestrogen receptor-positive and/or progesterone receptor-positive breast cancer (BC) has been shown to increase overall survival. However, arthralgias and myalgias are common adverse effects in patients treated with AI.

Objective:

To evaluate the frequency and characteristics of arthralgias and myalgias in patients with early BC-treated adjuvantly with AI in the Mastology Unit of the Oncology Service of the Hospital de Clínicas and the Departmental Hospital of Soriano. Materials and

methods:

A prospective, cross-sectional and descriptive study was performed. A questionnaire was administered to patients to assess the presence and characteristics of arthralgias and myalgias associated with AI. Statistical

analysis:

'Age' was described with measures of central tendency and dispersion. Qualitative variables were presented in absolute and relative frequencies. Logistic models were used to evaluate the association between patient characteristics, tumour characteristics, treatment characteristics and the presence of pain. Results were presented by odds ratio and p-value, using R software (version 4.1.2) with a significance threshold of 5%.

Results:

83 patients were included, with a median age of 69 years. 75.9% presented arthralgias and/or myalgias related to treatment, with an average intensity of 5-7. 80.9% received non-steroidal anti-inflammatory drugs (NSAIDs), achieving satisfactory analgesia. The presence of arthralgias and myalgias was significantly associated with age and time since the last menstrual period (LMP), being more frequent in patients older than 50 years and those with more than 5 years since the LMP.

Conclusion:

Approximately 70% of the patients presented arthralgias or myalgias. These findings suggest a possible role of oestrogen withdrawal in its mechanism of development. Multidisciplinary and translational research is crucial to evaluate the ethology and therapeutic options for patients with AI-related arthralgia.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ecancermedicalscience Año: 2024 Tipo del documento: Article País de afiliación: Uruguay Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ecancermedicalscience Año: 2024 Tipo del documento: Article País de afiliación: Uruguay Pais de publicación: Reino Unido